Compounded GLP-1 programs operating in 2026 must navigate the post-shortage legal framework, which includes restrictions on compounding drugs that are commercially available drugs under sections 503A and 503B of the FD&C Act
Ozempic helps manage type 2 diabetes and reduces cardiovascular risk
The proportion achieving at least a 15% reduction in body weight ranged from 4.9% to 39.8% across the elecoglipron groups, whereas only 2.7% of placebo patients achieved a similar reduction
Corrective actions become localized fixes (a new SOP, a training module, a password policy) rather than systemic remediation (role-based access design, technical restriction of deletion, independent audit trail review, validated archival, continuous monitoring of privileged actions)
In a phase 3 trial in subjects with obesity or overweight (BMI 27kg/m2), its use for 18 months achieved weight loss of up to 20.9%.87 Conclusions Low-grade inflammation underlies obesity and PsO/HS, and this inflammation has a negative impact on both conditions